{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:19:58Z","timestamp":1767140398558,"version":"build-2238731810"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s10072-022-06403-2","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T15:07:50Z","timestamp":1664464070000},"page":"329-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4141-0001","authenticated-orcid":false,"given":"Laure","family":"Le Goff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Seferian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Phelep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Rippert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Laure","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Cances","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Capucine","family":"de Lattre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Durigneux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaelle","family":"Gousse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Vincent-Genod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shams","family":"Ribault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Gomez Garcia de la Banda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Quijano-Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Sarret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Vuillerot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"issue":"1","key":"6403_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","volume":"4","author":"MD Mailman","year":"2002","unstructured":"Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B et al (2002) Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 4(1):20\u201326","journal-title":"Genet Med"},{"issue":"7","key":"6403_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","volume":"25","author":"R Finkel","year":"2015","unstructured":"Finkel R, Bertini E, Muntoni F, Mercuri E (2015) 209th ENMC International Workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7\u20139 November 2014, Heemskerk The Netherlands. Neuromuscul Disord 25(7):593\u2013602","journal-title":"Neuromuscul Disord"},{"issue":"18","key":"6403_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377(18):1723\u20131732","journal-title":"N Engl J Med"},{"issue":"7","key":"6403_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378(7):625\u2013635","journal-title":"N Engl J Med"},{"issue":"10","key":"6403_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R et al (2021) Risdiplam in type 1 spinal muscular atrophy. N Engl J Med 384(10):915\u2013923","journal-title":"N Engl J Med"},{"issue":"5","key":"6403_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, Xiong H, Zanoteli E et al (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385(5):427\u2013435","journal-title":"N Engl J Med"},{"issue":"4","key":"6403_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT et al (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20(4):284\u2013293","journal-title":"Lancet Neurol"},{"issue":"10","key":"6403_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C et al (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20(10):832\u2013841","journal-title":"Lancet Neurol"},{"issue":"1","key":"6403_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J (2020) Advances in treatment of spinal muscular atrophy \u2013 new phenotypes, new challenges, new implications for care. JND 7(1):1\u201313","journal-title":"JND"},{"issue":"9","key":"6403_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/archneur.59.9.1445","volume":"59","author":"ST Iannaccone","year":"2002","unstructured":"Iannaccone ST (2002) Outcome measures for pediatric spinal muscular atrophy. Arch Neurol 59(9):1445","journal-title":"Arch Neurol"},{"issue":"18","key":"6403_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377(18):1713\u20131722","journal-title":"N Engl J Med"},{"key":"6403_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1051\/medsci\/2019189","volume":"35","author":"C Pons","year":"2019","unstructured":"Pons C, Barri\u00e8re A, Bertrand G, Morard MD, Lilien C, Vuillerot C (2019) SMA: Des \u00e9chelles d\u2019\u00e9valuation motrice pour le public francophone. Med Sci (Paris) 35:24\u201328","journal-title":"Med Sci (Paris)"},{"key":"6403_CR13","unstructured":"A study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of risdiplam (RO7034067) in type 2 and 3 spinal muscular atrophy (SMA) participants (SUNFISH) [Internet]. ClinicalTrials.gov. Available from:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02908685. Accessed 1 Mar 2021"},{"issue":"2","key":"6403_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M et al (2018) Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28(2):103\u2013115","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"6403_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","volume":"15","author":"C B\u00e9rard","year":"2005","unstructured":"B\u00e9rard C, Payan C, Hodgkinson I, Fermanian J, The MFM Collaborative Study Group (2005) A motor function measure scale for neuromuscular diseases. Construction and validation study. Neuromuscular Disorders 15(7):463\u201370","journal-title":"Neuromuscular Disorders"},{"issue":"11","key":"6403_CR16","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.apmr.2013.04.001","volume":"94","author":"C de Lattre","year":"2013","unstructured":"de Lattre C, Payan C, Vuillerot C, Rippert P, de Castro D, B\u00e9rard C et al (2013) Motor function measure: validation of a short form for young children with neuromuscular diseases. Arch Phys Med Rehabil 94(11):2218\u20132226","journal-title":"Arch Phys Med Rehabil"},{"key":"6403_CR17","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, N.J: L. Erlbaum Associates 567"},{"issue":"1","key":"6403_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB, Bot SDM, de Boer MR, van der Windt DAWM, Knol DL, Dekker J et al (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34\u201342","journal-title":"J Clin Epidemiol"},{"key":"6403_CR19","unstructured":"Mercuri E, Deconinck N, Mazzone E, Nascimento A, Oskoui M, Saito K. Risdiplam in types 2 and type 3 spinal muscular atrophy. Submitted."},{"issue":"5","key":"6403_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0895-4356(99)00206-1","volume":"53","author":"JA Husted","year":"2000","unstructured":"Husted JA, Cook RJ, Farewell VT, Gladman DD (2000) Methods for assessing responsiveness. J Clin Epidemiol 53(5):459\u2013468","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"6403_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","volume":"8","author":"M Annoussamy","year":"2021","unstructured":"Annoussamy M, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C et al (2021) Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol 8(2):359\u2013373","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"6403_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13023-020-1348-2","volume":"15","author":"B Bartels","year":"2020","unstructured":"Bartels B, de Groot JF, Habets LE, Wijngaarde CA, Vink W, Stam M et al (2020) Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. Orphanet J Rare Dis 15(1):75","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"6403_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","volume":"15","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Lucibello S, Perulli M, Coratti G, de Sanctis R, Pera MC et al (2020) Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis 15(1):84","journal-title":"Orphanet J Rare Dis"},{"key":"6403_CR24","doi-asserted-by":"crossref","unstructured":"Chabanon A, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C et al (2018) Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. Mingozzi F, editor. PLoS One 13(7):e0201004.","DOI":"10.1371\/journal.pone.0201004"},{"issue":"4","key":"6403_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.nmd.2014.01.003","volume":"24","author":"E Mazzone","year":"2014","unstructured":"Mazzone E, De Sanctis R, Fanelli L, Bianco F, Main M, van den Hauwe M et al (2014) Hammersmith functional motor scale and motor function measure-20 in non ambulant SMA patients. Neuromuscul Disord 24(4):347\u2013352","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"6403_CR26","doi-asserted-by":"publisher","first-page":"82E","DOI":"10.1179\/jmt.2008.16.4.82E","volume":"16","author":"CE Cook","year":"2008","unstructured":"Cook CE (2008) Clinimetrics corner: the minimal clinically important change score (MCID): a necessary pretense. J Man Manipulative Therapy 16(4):82E-83E","journal-title":"J Man Manipulative Therapy"},{"issue":"4","key":"6403_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH (1989) Measurement of health status. Control Clin Trials 10(4):407\u2013415","journal-title":"Control Clin Trials"},{"key":"6403_CR28","doi-asserted-by":"publisher","first-page":"770423","DOI":"10.3389\/fneur.2021.770423","volume":"12","author":"T Duong","year":"2022","unstructured":"Duong T, Staunton H, Braid J, Barriere A, Trzaskoma B, Gao L et al (2022) A patient-centered evaluation of meaningful change on the 32-item motor function measure in spinal muscular atrophy using qualitative and quantitative data. Front Neurol 12:770423","journal-title":"Front Neurol"},{"key":"6403_CR29","doi-asserted-by":"crossref","unstructured":"Trundell D, Le Scouiller S, Le Goff L, Gorni K, Vuillerot C (2020) Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with type 2 or non-ambulant type 3 spinal muscular atrophy. Martinuzzi A, editor. PLoS One 15(9):e0238786.","DOI":"10.1371\/journal.pone.0238786"}],"updated-by":[{"DOI":"10.1007\/s10072-022-06522-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000}}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06403-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06403-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06403-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:03:32Z","timestamp":1672963412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06403-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["6403"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06403-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"17 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10072-022-06522-w","URL":"https:\/\/doi.org\/10.1007\/s10072-022-06522-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Hospices Civils de Lyon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"LS has served as a consultant or advisory board member for Novartis, Novartis Gene Therapies, Cytokinetics, Scholar Rock, Biogen, and Roche. CC has received advisory fees from Novartis Gene Therapies, Roche, and Pfizer and is a site principal investigator for Biogen and Roche clinical trials. LLG has received nonfinancial support from Biogen, Allergan, and Ipsen and consultancy fees from Roche and Novartis Gene Therapies. CV has received grants and advisory fees from Biogen and advisory fees from Roche and Novartis Gene Therapies. SQR is a site principal investigator for clinical trials of Biogen, Novartis Gene Therapies, and Roche has served on advisory boards for Biogen, Novartis Gene Therapies, and Roche, and has received travel and speaker honoraria from Biogen, Novartis and Roche. CS has received advisory fees from Biogen and nonfinancial support from Biogen, Roche and Novartis Gene Therapies. GG and MLM have received nonfinancial support from Biogen. CDL has served as consultant for Biogen and Roche. MGGB has served as consultation for Biogen, Novartis Gene Therapies, and Roche. AP, PR, DVG, SR, JD, and AS declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}